Literature DB >> 19048312

Exploring the binding of HIV-1 integrase inhibitors by comparative residue interaction analysis (CoRIA).

Devendra K Dhaked1, Jitender Verma, Anil Saran, Evans C Coutinho.   

Abstract

Since the recognition of HIV-1 integrase as a novel and rational target for HIV therapeutics, remarkable progress has been made in the development of integrase inhibitors. Computational techniques have played a critical role in accelerating research in this area. However, most previous computational studies were based solely on ligand information. In the present work, we describe the application of one of our recently developed receptor-based 3D-quantitative structure activity relationships (QSAR) methods, i.e. comparative residue interaction analysis (CoRIA), in exploring the events involved in ligand-integrase binding. In this methodology, the non-bonded interaction energies (van der Waals and Coulombic) of the inhibitors with individual active site residues of the integrase enzyme are calculated and, along with other thermodynamic descriptors, are correlated with biological activity using chemometric methods. Different combinations of descriptors were used to develop three types of QSAR models, all of which were found to be statistically significant by internal and external validation. This is the first report of such a dedicated receptor-based 3D-QSAR approach being applied to comprehend the integrase-inhibitor recognition process. In addition, the study was performed on 13-different series of inhibitors, thereby exploring the most structurally diverse data set ever used in understanding the inhibition of HIV-1 integrase. The major advantage of this technique is that it can quantitatively extract crucial residues and identify the nature of interactions between the ligand and receptor that modulate activity. The models suggest that Asp64, Thr66, Val77, Asp116, Glu152 and Lys159 are the key residues influencing the binding of ligands with the integrase enzyme, and the majority of these results are in line with earlier studies. The approach facilitates easy lead-to-hit conversion and design of novel inhibitors by optimisation of the interaction of ligands with these specific residues of the integrase enzyme.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19048312     DOI: 10.1007/s00894-008-0399-4

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  87 in total

1.  The Protein Data Bank.

Authors:  H M Berman; J Westbrook; Z Feng; G Gilliland; T N Bhat; H Weissig; I N Shindyalov; P E Bourne
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  3D-QSAR and molecular modeling of HIV-1 integrase inhibitors.

Authors:  Mahindra T Makhija; Vithal M Kulkarni
Journal:  J Comput Aided Mol Des       Date:  2002-03       Impact factor: 3.686

3.  Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies.

Authors:  Xiao-hui Ma; Xiao-yi Zhang; Jian-jun Tan; Wei-zu Chen; Cun-xin Wang
Journal:  Acta Pharmacol Sin       Date:  2004-07       Impact factor: 6.150

4.  Comparison of multiple molecular dynamics trajectories calculated for the drug-resistant HIV-1 integrase T66I/M154I catalytic domain.

Authors:  Alessandro Brigo; Keun Woo Lee; Gabriela Iurcu Mustata; James M Briggs
Journal:  Biophys J       Date:  2005-03-11       Impact factor: 4.033

5.  Cluster analysis and three-dimensional QSAR studies of HIV-1 integrase inhibitors.

Authors:  Hongbin Yuan; Abby Parrill
Journal:  J Mol Graph Model       Date:  2005-01       Impact factor: 2.518

Review 6.  The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection.

Authors:  Michael Rowley
Journal:  Prog Med Chem       Date:  2008

7.  Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase.

Authors:  Wim G Verschueren; Inge Dierynck; Katie I E Amssoms; Lili Hu; Paul M J G Boonants; Geert M E Pille; Frits F D Daeyaert; Kurt Hertogs; Dominique L N G Surleraux; Piet B T P Wigerinck
Journal:  J Med Chem       Date:  2005-03-24       Impact factor: 7.446

8.  Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors.

Authors:  Raveendra Dayam; Tino Sanchez; Omoshile Clement; Robert Shoemaker; Shizuko Sei; Nouri Neamati
Journal:  J Med Chem       Date:  2005-01-13       Impact factor: 7.446

9.  Diarylsulfones, a novel class of human immunodeficiency virus type 1 integrase inhibitors.

Authors:  N Neamati; A Mazumder; H Zhao; S Sunder; T R Burke; R J Schultz; Y Pommier
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

10.  Binding modes of two novel dinucleotide inhibitors of HIV-1 integrase.

Authors:  Sven Guenther; Vasu Nair
Journal:  Bioorg Med Chem Lett       Date:  2002-08-19       Impact factor: 2.823

View more
  3 in total

Review 1.  Computer tools in the discovery of HIV-1 integrase inhibitors.

Authors:  Chenzhong Liao; Marc C Nicklaus
Journal:  Future Med Chem       Date:  2010-07       Impact factor: 3.808

2.  De novo design of 7-aminocoumarin derivatives as novel falcipain-3 inhibitors.

Authors:  Anand S Chintakrindi; Mushtaque S Shaikh; Evans C Coutinho
Journal:  J Mol Model       Date:  2011-07-23       Impact factor: 1.810

Review 3.  Raltegravir: molecular basis of its mechanism of action.

Authors:  Jean-Francois Mouscadet; Luba Tchertanov
Journal:  Eur J Med Res       Date:  2009-11-24       Impact factor: 2.175

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.